OABI vs OCUL

OmniAb, Inc. vs Ocular Therapeutix, Inc. — Valuation Comparison 2026

OABI

Biotechnology
OmniAb, Inc.
Quality
5.8
out of 10
Value Trap
26
LOW
Price
$2.72
Last close
Models
9/13
Active
VS

OCUL

Biotechnology
Ocular Therapeutix, Inc.
Quality
7.2
out of 10
Value Trap
18
SAFE
Price
$9.15
Last close
Models
11/13
Active

Model-by-Model Comparison

ModelType OABI Fair ValueOABI Upside OCUL Fair ValueOCUL Upside
Bayesian DCF Intrinsic $0.58 -78.7% $4.28 -53.2%
Earnings Power Value Intrinsic $2.78 -70.6%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $0.45 -83.5% $2.99 -63.7%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for OABI vs OCUL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OABI vs OCUL — Which Stock Is More Undervalued?

OCUL scores higher with a 7.2/10 quality rating vs OABI's 5.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing OmniAb, Inc. (OABI) and Ocular Therapeutix, Inc. (OCUL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OABI currently trades at $2.72 with a QOC of 5.8/10, while OCUL trades at $9.15 with a QOC of 7.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).